Microsoft WordDabrafenib GSK PSD March 13 final...docx

First Page		Document Content
Date: 2014-10-01 21:56:23 Melanoma Organochlorides Organofluorides Sulfonamides Vemurafenib BRAF Ipilimumab Dacarbazine End point of clinical trials Medicine Chemistry Oncology		Microsoft WordDabrafenib GSK PSD March 13 final...docx Add to Reading List Source URL: www.pbs.gov.au Download Document from Source Website File Size: 94,43 KB Share Document on Facebook

	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6 DocID: 1gamh - View Document
	PDF Document DocID: 1aW8t - View Document
	Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma (aBCC): 18-Month Update of the Pivotal ERIVANCE BCC Study Aleksandar Sekulic,1 Michael R. Migden,2 Nicole Basset-Seguin,3 Claus G DocID: 1axH7 - View Document
	New target: FGFR & c-MET Laurence Albiges Gustave Roussy Institute, Dana-Farber Cancer Institute New target : FGFR, c-MET DocID: 19uI3 - View Document
	PUBLIC SUMMARY DOCUMENT Product: Imatinib, tablet, 100 mg and 400 mg (as mesylate), Glivec® Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: NovemberPurpose of Application DocID: 197HX - View Document